Summary

Eligibility
for people ages 2-25 (full criteria)
Location
at UCSF
Dates
study started
study ends around
Principal Investigator
by Sabine Mueller (ucsf)
Headshot of Sabine Mueller
Sabine Mueller

Description

Summary

This phase I, first-in-human trial tests the safety, side effects, and best dose of genetically modified cells called KIND T cells after lymphodepletion (a short dose of chemotherapy) in treating patients who are HLA-A*0201-positive and have H3.3K27M-mutated diffuse midline glioma. KIND T cells are a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory into KIND T cells so they will recognize certain markers found in tumor cells. Drugs such as cyclophosphamide and fludarabine are chemotherapy drugs used to decrease the number of T cells in the body to make room for KIND T cells. Giving KIND T cells after cyclophosphamide and fludarabine may be more useful against cancer compared to the usual treatment for patients with H3.3K27M-mutated diffuse midline glioma (DMG).

Official Title

PNOC018 A Phase 1 Clinical Trial of Autologous T Cells Expressing a TCR Specific for H3.3K27M With Inhibition of Endogenous TCR (KIND T Cells) in HLA-A*0201-positive Participants With H3.3K27M-positive Diffuse Midline Gliomas

Details

Keywords

Diffuse Midline Glioma, H3 K27M-Mutant, Autologous T Cells, KIND T Cells, HLA-A*0201-Positive, Glioma, Cyclophosphamide, Fludarabine, Autologous Anti-H3.3K27M TCR-expressing T-cells

Eligibility

Location

  • University of California, San Francisco accepting new patients
    San Francisco California 94143 United States

Lead Scientist at University of California Health

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
University of California, San Francisco
ID
NCT05478837
Phase
Phase 1 Glioma Research Study
Study Type
Interventional
Participants
Expecting 12 study participants
Last Updated